Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis

NCT07503652 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.

NCT NCT07503652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07503652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Lead sponsor
First Hospital of China Medical University
Phase
Phase 4
Overall status
Recruiting
Start date
March 31, 2026
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis (ppp)